<DOC>
	<DOCNO>NCT00515450</DOCNO>
	<brief_summary>This randomize control , multi-center study carry assess efficacy GB-0998 compare plasmapheresis treatment generalize Myasthenia Gravis base change Quantitative Myasthenia Gravis score ( QMG score ) primary endpoint , addition , assess safety GB-0998</brief_summary>
	<brief_title>Efficacy Safety Study GB-0998 Treatment Generalized Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients diagnose generalize myasthenia gravis Patients control current therapy need plasmapheresis therapy Patients highdose steroid therapy month past year , also take steroid immunosuppressant day consent Patients dose increase new dose steroid immunosuppressant within 4 week prior enrollment Patients receive steroid pulse therapy , globulin therapy plasmapheresis therapy within 12 week prior enrollment Patients undergone thymectomy within 24 week prior enrollment Patients 3 point item bulbar symptom MGADL scale Patients severe hepatic disorder , severe renal disorder severe heat disorder Patients receive treatment malignant tumor Patients anamnesis shock hypersensitivity drug Patients diagnose hereditary fructose intolerance Patients anamnesis cerebral infarction symptom diseases Patients diagnose IgA deficiency past history Pregnant , lactating , probably pregnant patient , patient want become pregnant Patients administer investigational drug within 12 week consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Myasthenia Gravis</keyword>
</DOC>